CagriSema
PH-CAGRI-001
Specifications
- Purity (HPLC)
- 99%+
- Size
- 10mg
- Catalog No.
- PH-CAGRI-001
Description
CagriSema combines cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist, in a single research blend. The two peptides act on complementary appetite- and glucose-regulating pathways studied together for additive metabolic effects.
Mechanism of Action
Cagrilintide is an acylated, long-acting analog of the pancreatic hormone amylin that signals satiety through amylin and calcitonin receptors, slowing gastric emptying and reducing food intake. Semaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite via central GLP-1 receptors. Co-administering the two targets the amylin and GLP-1 systems simultaneously, a combination investigated for greater effects on body weight and glycemic control than either peptide alone.
Clinical Research: The REIMAGINE Phase 3 Program
In the phase 3a REIMAGINE 1 trial, adults with early type 2 diabetes inadequately controlled on diet and exercise received once-weekly cagrilintide-semaglutide for 40 weeks. The 2.4 mg + 2.4 mg dose lowered HbA1c by 1.8 percentage points and reduced body weight by 13.8%, versus 0.1 points and 1.4% with placebo (Aroda et al., Lancet Diabetes Endocrinol 2026).
Across the wider REIMAGINE program, CagriSema outperformed semaglutide alone: in REIMAGINE 2 it reduced HbA1c by 1.91 points versus 1.76 with semaglutide and produced 14.2% weight loss versus 10.2%, while in REIMAGINE 3 — added to basal insulin — it lowered HbA1c from 8.8% to 6.5% with weight reductions up to 12% and no severe hypoglycemia (HCPLive, 2026).
Research Applications
- Combined amylin / GLP-1 receptor pharmacology
- Obesity and body-weight regulation studies
- Type 2 diabetes and glycemic control research
- Appetite and energy-balance signaling
- Comparative studies versus single-agonist incretin therapy
Product Specifications
- Composition: Cagrilintide 5mg + Semaglutide 5mg (10mg total)
- Purity: ≥99% each component (HPLC verified)
- Form: Lyophilized powder
- Storage: -20°C, protected from light
References
- Aroda VR, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes (REIMAGINE 1). Lancet Diabetes Endocrinol. 2026. PMID: 42251860 · DOI: 10.1016/S2213-8587(26)00126-9
- CagriSema Outperforms Semaglutide Alone Across Phase 3 REIMAGINE Trials. HCPLive, 2026. REIMAGINE 3 results presented by Julio Rosenstock, MD, at ADA 2026.
Medically reviewed by Julio Rosenstock, MD.
Verification
Storage & Handling
Storage
CagriSema is supplied as a lyophilized powder. Keep it sealed, dry, and away from light until reconstitution.
Reconstitution
Let the vial reach room temperature before opening, then add solvent slowly down the vial wall — do not shake.
Stability
Lyophilized material is stable when frozen. Once reconstituted, keep it cold and minimise handling to preserve integrity.
Research Overview
CagriSema is a synthetic peptide compound used in laboratory research settings. Researchers studying metabolic regulation and energy homeostasis use this compound to investigate cellular signaling pathways, receptor binding affinities, and structure-activity relationships. Each batch is manufactured under controlled conditions and verified through HPLC and mass spectrometry analysis to ensure consistency across experimental replicates.
Documentation & Resources
- Certificate of Analysis for CagriSema — batch-specific purity and identity verification
- Research Blog — protocols, guides, and peptide research literature
- Research Use Policy — handling and compliance guidelines
Frequently Asked Questions
What purity is CagriSema?
Each lot of CagriSema is verified to 99%+ by HPLC and confirmed by mass spectrometry. Results are documented in a batch-specific Certificate of Analysis.
Does CagriSema include a Certificate of Analysis?
Yes. A batch-specific Certificate of Analysis for CagriSema documents its purity and identity and is available on our COA page.
How should CagriSema be stored?
CagriSema is supplied as a lyophilized powder. For short-term storage keep it refrigerated; for long-term storage keep it frozen, away from light and moisture.
How is CagriSema shipped?
Orders ship at a $15 flat rate, free on orders over $199, in discreet, insulated packaging. Domestic delivery typically takes 1–3 business days.
Can CagriSema be used on humans or animals?
No. CagriSema is supplied strictly for in-vitro laboratory research. It is not for human or veterinary use, consumption, or diagnostic or clinical applications.
